We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Cheminformatics Based Machine Learning Approaches for Assessing Glycolytic Pathway Antagonists of Mycobacterium tuberculosis.
BACKGROUND: Tuberculosis is the second leading cause of death from an infectious disease worldwide after HIV, thus reasoning the expeditions in antituberculosis research. The rising number of cases of infection by resistant forms of M. tuberculosis has given impetus to the development of novel drugs that have different targets and mechanisms of action against the bacterium.
METHODS: In this study, we have used machine learning algorithms on the available high throughput screening data of inhibitors of fructose bisphosphate aldolase, an enzyme central to the glycolysis pathway in M. tuberculosis, to build predictive classification models to identify actives against Mycobacterium tuberculosis, the causative organism of tuberculosis. We used Naïve Bayes, Random Forest and C4.5 J48 algorithms available from Weka were used for building predictive classification models. Additionally, a set of most relevant attributes was selected using genetic search algorithm which offered improved model performance by avoiding over fitting and generating faster and cost effective models.
RESULTS: The model built using machine learning methods in this study provided good accuracy of classification of test compounds which suggests that in silico methods can be successfully used for screening of large datasets to identify potential drug leads. The substructure fragment analysis serves to further potentiate the M. tuberculosis drug development process as it would facilitate identification of structural fragments that are responsible for biological activity against this crucial glycolysis pathway target.
METHODS: In this study, we have used machine learning algorithms on the available high throughput screening data of inhibitors of fructose bisphosphate aldolase, an enzyme central to the glycolysis pathway in M. tuberculosis, to build predictive classification models to identify actives against Mycobacterium tuberculosis, the causative organism of tuberculosis. We used Naïve Bayes, Random Forest and C4.5 J48 algorithms available from Weka were used for building predictive classification models. Additionally, a set of most relevant attributes was selected using genetic search algorithm which offered improved model performance by avoiding over fitting and generating faster and cost effective models.
RESULTS: The model built using machine learning methods in this study provided good accuracy of classification of test compounds which suggests that in silico methods can be successfully used for screening of large datasets to identify potential drug leads. The substructure fragment analysis serves to further potentiate the M. tuberculosis drug development process as it would facilitate identification of structural fragments that are responsible for biological activity against this crucial glycolysis pathway target.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app